

10/574,649

=> d his

(FILE 'HOME' ENTERED AT 13:16:12 ON 02 APR 2009)

FILE 'REGISTRY' ENTERED AT 13:16:37 ON 02 APR 2009

L1	STRUCTURE UPLOADED
L2	1 S L1
L3	39 S L1 SSS FUL
L4	35 S L3 AND CAPLUS/LC
L5	4 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 13:18:41 ON 02 APR 2009

L6	14 S L3
L7	12 S L6 NOT (2009/SO OR 2008/SO OR 2007/SO OR 2006/SO OR 2005/SO)

=> d ibib abs hitstr total

L7 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2006:579433 CAPLUS

DOCUMENT NUMBER: 145:62888

TITLE: Preparation of N-indazolyl-N'-chromanylurea derivatives as VR1 inhibitors for treatment of pain
 INVENTOR(S): Gontsyan, Arthur; Bayburt, Erol K.; Schmidt, Robert G.; Lee, Chih-Hung; Brown, Brian S.; Jinkerson, Tammie K.; Koenig, John R.; Daanen, Jerome F.; Latshaw, Steven P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 68 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060128689	A1	20060615	US 2005-285448	20051122
AU 2005316972	A1	20060622	AU 2005-316972	20051122
CA 2588909	A1	20060622	CA 2005-2588909	20051122
WO 2006065484	A2	20060622	WO 2005-US42545	20051122
WO 2006065484	A3	20090219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1844038	A2	20071017	EP 2005-825417	20051122
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008532925	T	20080821	JP 2007-543471	20051122
IN 2007DN04797	A	20070824	IN 2007-DN4797	20070621
KR 2007086607	A	20070827	KR 2007-714371	20070622
PRIORITY APPLN. INFO.:			US 2004-630636P	P 20041124
			WO 2005-US42545	W 20051122

OTHER SOURCE(S): CASREACT 145:62888; MARPAT 145:62888

GI




AB The title N-indazolyl-N'-chromanylurea derivs. I [wherein m and n = independently 0-4; A, B, D, and E = N or (un)substituted CH; L = a bond or alkylene; X = O or (un)substituted NH; Y = a bond, O, S, or (un)substituted NH; Z = (un)substituted monocyclic or bicyclic ring; R1 and R2 = independently H, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, (hetero)aryl, etc.; R3 = H, OH, (halo)alkyl, or (halo)alkoxy; with provisos], prodrugs, or pharmaceutically acceptable salts thereof as inhibitors of vanilloid receptor subtype 1 (VR1) for treatment of pain. For example, II was prepared in a multi-step synthesis. The title compds. showed antagonistic activity with IC50 from 6000 nM to 1 nM against VR1. The compds. are useful for controlling pain and urinary disorders, such as osteoarthritic pain, inflammatory pain, bladder overactivity, urinary incontinence, etc. (no data).

IT 890837-83-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-indazolyl-N'-chromanylurea derivs. as VR1 inhibitors for treatment of pain)

RN 890837-83-9 CAPLUS

CN Urea, N-1H-indazol-4-yl-N'-(2,3,4,5-tetrahydro-1-(phenylmethyl)-1H-1-benzazepin-5-yl)- (CA INDEX NAME)



L7 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2005:371225 CAPLUS

DOCUMENT NUMBER: 142:430156

TITLE: Preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia

INVENTOR(S): Cao, Guoqing; Escribano, Ana Maria; Fernandez, Maria Carmen; Fields, Todd; Gernert, Douglas Linn; Cioffi, Christopher Lawrence; Herr, Robert Jason; Mantlo, Nathan Bryan; Martin De La Nava, Eva Maria; Mateo Herranz, Ana Isabel; Mayhugh, Daniel Ray; Wang, Xiaodong

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 188 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037796	A1	20050428	WO 2004-US30907	20041007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004282101	A1	20050428	AU 2004-282101	20041007
CA 2537942	A1	20050428	CA 2004-2537942	20041007
EP 1670768	A1	20060621	EP 2004-793889	20041007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014186	A	20061031	BR 2004-14186	20041007
CN 1863778	A	20061115	CN 2004-80029540	20041007
JP 2007508301	T	20070405	JP 2006-533949	20041007
IN 2006KN00372	A	20070316	IN 2006-KN372	20060220
US 20070254869	A1	20071101	US 2006-574649	20060330
KR 2006085675	A	20060727	KR 2006-706837	20060407
MX 2006003927	A	20080207	MX 2006-3927	20060407
NO 2006002074	A	20060508	NO 2006-2074	20060508
PRIORITY APPLN. INFO.:			US 2003-509736P	P 20031008
			WO 2004-US30907	W 20041007
OTHER SOURCE(S):		CASREACT 142:430156; MARPAT 142:430156		
GI				



AB Title compds. I [n, m, q = 0-3; p = 1-2; R1 = OH, alkyl, aryl, etc.; R2 = H, OH, halo, etc.; R3 = H; R4 = (un)substituted amino; R5 = H, OH, halo, etc.; R6 = allyl alc., alkoxy, etc.] are prepared For instance, 5-[acetyl(3,5-bis(trifluoromethyl)benzyl)amino]-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid iso-Pr ester (II) is prepared in 8 steps from 2-aminobenzoic acid Me ester, Et 4-bromobutyrate and 3,5-bis(trifluoromethyl)benzylamine. II has an IC50 of 293 nM for cholesterol ester transfer protein (CETP). I are useful for treating atherosclerosis and its sequelae.

IT 851044-91-2P 851044-92-3P 851044-94-5P
851044-95-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851044-91-2 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[(5S)-1-(cyclopentylmethyl)-2,3,4,5-tetrahydro-7-methyl-8-(trifluoromethyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 851044-92-3 CAPLUS

CN 1H-1-Benzazepine-1-pentanoic acid, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-β,β,7-trimethyl-8-(trifluoromethyl)-, methyl ester, (5S)- (CA

INDEX NAME)


Absolute stereochemistry.



RN 851044-94-5 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[(9S)-5-(cyclopentylmethyl)-2,2-difluoro-6,7,8,9-tetrahydro-5H-1,3-dioxolo[4,5-h][1]benzazepin-9-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 851044-95-6 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[1-(cyclopentylmethyl)-2,3,4,5,7,9-hexahydro-1H-furo[3,4-h]-1-benzazepin-5-yl]- (CA INDEX NAME)

10/574,649




REFERENCE COUNT:

1


THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:407208 CAPLUS
 DOCUMENT NUMBER: 111:7208
 ORIGINAL REFERENCE NO.: 111:1379a,1382a
 TITLE: 11-Alkoxydibenzo[b,e]azepin-6-ones with anticonvulsant activity
 AUTHOR(S): Pestellini, Vittorio; Viti, Giovanni; Nannicini, Rossano; Borsini, Franco; Furio, Martino; Lecci, Alessandro; Volterra, Giovanna; Meli, Alberto
 CORPORATE SOURCE: Res. Div., Menarini Farm., Florence, 50131, Italy
 SOURCE: European Journal of Medicinal Chemistry (1988), 23(5), 473-6
 CODEN: EJMC5; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 111:7208
 GI



AB The synthesis and anticonvulsant properties of new 5,6-dihydrodibenzo[b,e]azepin-6-ones, e.g., I (R = H, Me; R1 = NHCHMe2, NHAc, NHR2, OEt, OH, OMe, OCHMe2, OBu, OPh; R2 = cyclohexyl, 2-pyrimidinyl) are presented. Structure-activity relationships of various derivs. substituted in positions 5 and 11, as well as the importance of the steric hindrance of the substituents on biol. activity are shown.
 IT 121112-92-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and anticonvulsant activity of)
 RN 121112-92-3 CAPLUS
 CN Acetamide, N-(6,11-dihydro-5-methyl-6-oxo-5H-dibenz[b,e]azepin-11-yl)-
 (CA INDEX NAME)



L7 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1987:43983 CAPLUS

DOCUMENT NUMBER: 106:43983

ORIGINAL REFERENCE NO.: 106:7173a,7176a

TITLE: Serum pretreatment for tricyclic antidepressant drug assays and kit therefor

INVENTOR(S): Collins, Christine Glen; Pankay, Susan; Jaklitsch, Anna

PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA

SOURCE: Eur. Pat. Appl., 39 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 177344	A2	19860409	EP 1985-307045	19851002
EP 177344	A3	19861230		
EP 177344	B1	19920408		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4652529	A	19870324	US 1984-657319	19841002
CA 1265981	A1	19900220	CA 1985-492000	19851001
AT 74660	T	19920415	AT 1985-307045	19851002
CA 1269598	A2	19900529	CA 1989-598511	19890502
PRIORITY APPLN. INFO.:			US 1984-657319	A 19841002
			CA 1985-492000	A3 19851001
			EP 1985-307045	A 19851002

OTHER SOURCE(S): MARPAT 106:43983

AB Blood serum or plasma samples for tricyclic antidepressant drug assays are pretreated to purify a sample substantially free from metabolites and in a form useful for drug assay determination. A sample is passed through a column containing alkylated silica gel. The column is washed with a mixture of an aqueous

buffer (pH 3.5-5.0) and organic solvent containing Cl-6 and 1-5 heteroatoms selected from O, N, and S to remove metabolites. The tricyclic antidepressant drug is eluted with a solvent mixture of an aqueous buffer (pH 6-8) and ≥ 1 organic solvents containing Cl-6 and 1-5 heteroatoms selected from O, N, and S. For example, a sample for nortriptyline assay was placed on a C-2 (Et) column which was prewashed with MeOH and H₂O. Contaminating metabolites were removed from the column with a solution

containing AcONa, heptane sulfonate and MeCN. The drug was eluted with a solution containing MeCN, MeOH, and K₂HPO₄. The eluate was collected and used in an enzyme immunoassay for nortriptyline determination. Thus, a sensitive, rapid, and

efficient method is provided for treating samples for tricyclic antidepressant drug assays which result in accurate detns. of the drug.


IT 102973-92-2P 102973-93-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of)

RN 102973-92-2 CAPLUS


CN Carbamic acid, [3-[10,11-dihydro-10-[[[methylthio]acetyl]amino]-5H-dibenz[b,f]azepin-5-yl]propyl]methyl-, 2,2,2-trichloroethyl ester (9CI)
(CA INDEX NAME)

10/574,649



RN 102973-93-3 CAPLUS

CN Acetamide, N-[10,11-dihydro-5-[3-(methylamino)propyl]-5H-dibenz[b,f]azepin-10-yl]-2-mercapto- (CA INDEX NAME)




L7 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1986:424199 CAPLUS
 DOCUMENT NUMBER: 105:24199
 ORIGINAL REFERENCE NO.: 105:4069a,4072a
 TITLE: Demethylimipramine derivative-protein conjugates
 INVENTOR(S): Pirió, Marcel R.; Singh, Prithipal
 PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
 SOURCE: U.S., 9 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4551275	A	19851105	US 1984-592492	19840323
PRIORITY APPLN. INFO.:			US 1984-592492	19840323
OTHER SOURCE(S):		CASREACT 105:24199; MARPAT 105:24199		

GI




I




II

AB Imipramines I (R = H, R₂ = O; R₁ = H, carbalkoxy; Z = aliphatic doubling radical containing C, N, O, and S atoms; Z₁ = O, S, NH; n, m = 0, 1; R₂ = NH₂, SH, protein residue) were prepared; I (R₂ = protein residue) showed their usefulness in assays for demethylimipramine. 10-Oxoimipramine was converted to demethylimipramine derivative II in a series of reactions; and II formed a reaction product with BrCH₂CONHCH₂CO₂H-glucose 6-phosphate dehydrogenase.

IT 102973-92-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of, by zinc)
 RN 102973-92-2 CAPLUS
 CN Carbamic acid, [3-[10,11-dihydro-10-[[[(methylthio)acetyl]amino]-5H-dibenz[b,f]azepin-5-yl]propyl]methyl-, 2,2,2-trichloroethyl ester (9CI)
 (CA INDEX NAME)




IT 102973-93-3DP, reaction products with (bromoacetyl)glycine-protein
 conjugates
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for immunoassay)
 RN 102973-93-3 CAPLUS
 CN Acetamide, N-[10,11-dihydro-5-[3-(methylamino)propyl]-5H-dibenz[b,f]azepin-
 10-yl]-2-mercapto- (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1982:555906 CAPLUS
 DOCUMENT NUMBER: 97:155906
 ORIGINAL REFERENCE NO.: 97:25793a,25796a
 TITLE: Biotransformation of metapramine in three animal species (dog, rabbit, rat), and in man
 AUTHOR(S): Decouvelaere, B.; Terlain, B.; Bieder, A.
 CORPORATE SOURCE: Inst. Biopharm., Rhone-Poulenc, Antony, 92160, Fr.
 SOURCE: Therapie (1982), 37(3), 249-57
 CODEN: THERAP; ISSN: 0040-5957
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI




AB Fourteen urinary and fecal metabolites of orally administered metapramine (I) [21730-16-5] were identified in dogs, rabbits, rats, and humans. The major metabolic pathway in all species was demethylation, resulting primarily in 10-methylamino-10,11-dihydrodibenz[b,f]azepine [69546-00-5]. Other metabolic pathways involved acetylation, hydroxylation, desamination, oxidation, dehydration, and ring contraction, the latter to form acridones. I metabolism was similar in all species examined, both qual. and quant.
 IT 21737-68-8 83215-35-4
 RL: BIOL (Biological study)
 (as metapramine metabolite, in humans and laboratory animals)
 RN 21737-68-8 CAPLUS
 CN Acetamide, N-(10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)- (CA INDEX NAME)



RN 83215-35-4 CAPLUS
 CN Urea, N-(10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)- (CA INDEX NAME)

10/574,649



L7 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1972:501405 CAPLUS

DOCUMENT NUMBER: 77:101405

ORIGINAL REFERENCE NO.: 77:16711a,16714a

TITLE: Pharmacologically active
10,11-dihydrodibenz[b,f]azepines

INVENTOR(S): Fouché, Jean; Leger, Andre

PATENT ASSIGNEE(S): Societe des usines chimiques de Rhone-Poulenc

SOURCE: Fr. Demande, 34 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2092877	A5	19720128	FR 1970-23779	19700626
FR 2092877	B1	19730810		


PRIORITY APPLN. INFO.: FR 1970-23779 19700626

GI For diagram(s), see printed CA Issue.

AB Title compds. (I, R = H, NH₂, NHMe, NHC(O)Et; R₁ = H, NH₂, NHMe; R₂, R₃, R₄, R₅ = H, Cl) were prepared. Substituted o-HO₂CCH₂C₆H₄NMePh treated with polyphosphoric acid or (Me₂N)₃PO gave substituted 5-methyl-10,11-dihydrodibenz[b,f]azepin-10-one, the oxime of which, treated with Na-Hg, gave I [R = NH₂] (II). II treated with formylacetic anhydride gave I [R = HCONH], which, treated with LiAlH₄, gave I [R = MeNH]. I (R₁ = MeNH) was similarly prepared. Formulations of compns. utilizing I were given. I were reported to be active as analgesics, antidepressants, anticonvulsants, and tranquilizers.


IT 31376-32-6P 31376-43-9P 31376-53-1P
31376-73-5P 31380-00-4P 31380-01-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 31376-32-6 CAPLUS


CN Formamide, N-(7-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
(CA INDEX NAME)

RN 31376-43-9 CAPLUS


CN Formamide, N-(6-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
(CA INDEX NAME)




RN 31376-53-1 CAPLUS
 CN Formamide, N-(1-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)



RN 31376-73-5 CAPLUS
 CN Formamide, N-(3-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)




RN 31380-00-4 CAPLUS
 CN Formamide, N-(4-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)



RN 31380-01-5 CAPLUS

10/574,649


CN Carbamic acid, (2-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 1972:434370 CAPLUS
 DOCUMENT NUMBER: 77:34370
 ORIGINAL REFERENCE NO.: 77:5723a,5726a
 TITLE: Pharmacologically active
 10,11-dihydrodibenz[b,f]azepine derivatives
 INVENTOR(S): Fouche, Jean; Leger, Andre
 PATENT ASSIGNEE(S): Societe des usines chimiques de Rhone-Poulenc
 SOURCE: Fr. Demande, 18 pp
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2069831	A5	19710910	FR 1969-27226	19690807
NL 7011296	A	19710209	NL 1970-11296	19700730
SU 370777	A3	19730215	SU 1970-1466527	19700803
SU 399124	A3	19730927	SU 1970-1663229	19700803
CS 163771	B2	19751107	CS 1970-5442	19700804
CS 163772	B2	19751107	CS 1970-7446	19700804
ZA 7005448	A	19710428	ZA 1970-5448	19700806
CH 516560	A	19711215	CH 1970-516560	19700806
CH 518283	A	19720131	CH 1970-518283	19700806
PL 82685	B1	19751031	PL 1970-142553	19700806
DE 2039396	A	19710218	DE 1970-2039396	19700807
DE 2064879	A	19720210	DE 1970-2064879	19700807
AT 299211	B	19720612	AT 1970-7211	19700807
AT 301556	B	19720911	AT 1971-5815	19700807
GB 1301366	A	19721229	GB 1970-1301366	19700807
GB 1301367	A	19721229	GB 1970-1301367	19700807
JP 49039275	B	19741024	JP 1971-22821	19710413
PRIORITY APPLN. INFO.:			FR 1969-27226	A 19690807
GI	For diagram(s), see printed CA Issue.			
AB	Aminodibenzazepines I useful as antidepressants, analgesics, anticonvulsants, and tranquilizers in animals at a daily oral dose of 2-50 mg/kg, were prepared. Thus, stirring the dibenzazepinone oxime II with Na-H and aqueous EtOH at 70° for 6 hr, with addition of AcOH to keep the pH at 8-9 gave I (R1 = Me, R2 = R3 = H) (III). Compound II was prepared from 2-bromo-4-chloro-N-benzoylaniline through a sequence of reactions.			
IT	31379-94-9P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)			
RN	31379-94-9 CAPLUS			
CN	Formamide, N-(8-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)- (CA INDEX NAME)			

10/574,649



L7 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:99914 CAPLUS
 DOCUMENT NUMBER: 74:99914
 ORIGINAL REFERENCE NO.: 74:16265a,16268a
 TITLE: Pharmaceutical
 chloro-5-methyl-11-amino-10,11-dihydro-5H-
 dibenz[b,f]azepines
 Fouché, Jean; Leger, Andre
 INVENTOR(S): Rhone-Poulenc S. A.
 PATENT ASSIGNEE(S): Ger. Offen., 58 pp.
 SOURCE: CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2039396	A	19710218	DE 1970-2039396	19700807
FR 2069831	A5	19710910	FR 1969-27226	19690807
			FR 1969-27226	A 19690807

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) and their pharmacol. compatible salts, which were active on the central nervous system as antidepressants, analgesics, anticonvulsants, and tranquilizers, were prepared if R = H from the 11-hydroxyimino derivative by reduction with NaHg or if R = Me from the 11-formamido derivative by reduction with LiAlH₄. Prepared were I (R = H, Me, resp.) with Cl in positions 2-4 and 6-9. Formulations containing I are reported.

IT 31376-32-6P 31376-43-9P 31376-53-1P


31376-64-4P 31376-73-5P 31379-94-9P

31380-00-4P 31380-01-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 31376-32-6 CAPLUS

CN Formamide, N-(7-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)




RN 31376-43-9 CAPLUS


CN Formamide, N-(6-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)




RN 31376-53-1 CAPLUS
 CN Formamide, N-(1-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)



RN 31376-64-4 CAPLUS
 CN Formamide, N-(2-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)




RN 31376-73-5 CAPLUS
 CN Formamide, N-(3-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
 (CA INDEX NAME)




RN 31379-94-9 CAPLUS

CN Formamide, N-(8-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
(CA INDEX NAME)




RN 31380-00-4 CAPLUS

CN Formamide, N-(4-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-
(CA INDEX NAME)



RN 31380-01-5 CAPLUS

CN Carbamic acid, (2-chloro-10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:76346 CAPLUS
 DOCUMENT NUMBER: 74:76346
 ORIGINAL REFERENCE NO.: 74:12387a,12390a
 TITLE: Fungicidal 10-acylamino-10,11-dihydrodibenz[b,f]azepines
 INVENTOR(S): Fouche, Jean; Leger, Andre
 PATENT ASSIGNEE(S): Rhone-Poulenc S. A.
 SOURCE: Ger. Offen., 19 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2031236	A	19710107	DE 1970-2031236	19700624
DE 2031236	B2	19750925		
DE 2031236	C3	19760429		
FR 2045705	A5	19710305	FR 1969-21176	19690624
FR 2086796	A6	19711231	FR 1970-12838	19700409
NL 7008793	A	19701229	NL 1970-8793	19700616
ZA 7004238	A	19710224	ZA 1970-4238	19700622
GB 1253486	A	19711117	GB 1970-1253486	19700622
US 3792042	A	19740212	US 1970-48450	19700622
BE 752411	A	19701223	BE 1970-752411	19700623
CH 509758	A	19710715	CH 1970-509758	19700623
IL 34788	A	19730430	IL 1970-34788	19700623
SE 370237	B	19741007	SE 1970-8694	19700623
SE 381162	B	19751201	SE 1973-1346	19700623
DK 133466	B	19760524	DK 1970-3248	19700623
AT 300464	B	19720725	AT 1970-5687	19700624
JP 48037036	B	19731108	JP 1971-11358	19710305
US 3882235	A	19750506	US 1973-384419	19730801
DK 7405171	A	19750526	DK 1974-5171	19741001
DK 133453	B	19760524		

PRIORITY APPLN. INFO.:
 FR 1969-21176 A 19690624
 FR 1970-12838 A 19700409
 US 1970-48450 A3 19700622
 DK 1970-3248 A 19700623


GI For diagram(s), see printed CA Issue.

AB The title compds. (I), active especially against Erysiphe polyphaga, E. lini, Podosphaera leucotricha, Sphaerotheca pannosa, or Microsphaera berberidis, were prepared by acylation with ClCOR1 of the 10-amino derivs., prepared by known reduction of the oxime, in the presence of a base, e.g. pyridine. Among 17 compds. prepared were I (R and R1 given): Me, Et; H, Et; Me, Pr; Et, Et; H, hexyl; Pr, Et.

IT 30761-57-0P 30761-65-0P 30761-66-1P
 30761-67-2P 30761-68-3P 30761-69-4P
 30761-74-1P 30761-75-2P 30761-81-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 30761-57-0 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-methyl-, ethyl ester (8CI) (CA INDEX NAME)




RN 30761-65-0 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-methyl-, propyl ester (8CI) (CA INDEX NAME)




RN 30761-66-1 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-methyl-, isopropyl ester (8CI) (CA INDEX NAME)




RN 30761-67-2 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-methyl-, butyl ester (8CI) (CA INDEX NAME)




RN 30761-68-3 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-methyl-, isobutyl ester (8CI) (CA INDEX NAME)




RN 30761-69-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 5-ethyl-10,11-dihydro-, ethyl ester (8CI) (CA INDEX NAME)




RN 30761-74-1 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-methyl-, heptyl ester (8CI) (CA INDEX NAME)




RN 30761-75-2 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-propyl-, ethyl ester (8CI) (CA INDEX NAME)



RN 30761-81-0 CAPLUS

CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-5-methyl-, methyl ester (8CI) (CA INDEX NAME)



L7 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:53578 CAPLUS

DOCUMENT NUMBER: 74:53578

ORIGINAL REFERENCE NO.: 74:8633a,8636a

TITLE: 10,11-Dihydrodibenz[b,f]azepines, having central nervous system activity

PATENT ASSIGNEE(S): Societe des usines chimiques de Rhone-Poulenc

SOURCE: Fr. M., 5 pp.

CODEN: FMXXAJ

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 6616		19690224	FR	19670414

OTHER SOURCE(S): MARPAT 74:53578

GI For diagram(s), see printed CA Issue.


AB The 10-aminodibenz[b,f]azepines (I) are prepared by different methods. The oxime (II) is treated with Na and the 10-amino derivative obtained is treated with H₂CO to give I (R = R₁ = Me). The 10-formamido compound is reduced with LiAlH₄ to give I (R = H, R₁ = Me).

IT 21737-56-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 21737-56-4 CAPLUS

CN Formamide, N-(10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)- (CA INDEX NAME)



L7 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1969:57689 CAPLUS
 DOCUMENT NUMBER: 70:57689
 ORIGINAL REFERENCE NO.: 70:10829a
 TITLE: 10-Amino-10,11-dihydrodibenzo[b,f]azepines
 INVENTOR(S): Fouche, Jean C. L.; Gueremy, Claude G. A.
 PATENT ASSIGNEE(S): Rhone-Poulenc S. A.
 SOURCE: S. African, 3/ pp.
 CODEN: SFXXAB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 6800345		19680619	ZA	
DE 1695666			DE	
FR 1532301			FR	
FR 94320			FR	
GB 1180164			GB	
GB 1180165			GB	
US 3622565		19711123	US	19680117
PRIORITY APPLN. INFO.:			FR	19670118
			FR	19671109

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) (R1, R2, R3 = H, Me, or Et) were prepared either from the oximes IIa of II or from I with other R2 and R3. Thus, 13 g. Na was added in 90 min. to 19 g. IIa (R = Me) in 200 ml. BuOH at 100°, the mixture refluxed 20 min. and worked up to give, after extraction with 2N MeSO3H,

11.5 g. I (R1 = Me, R2 = R3 = H) (III), m. 96° (MeCN). The following I (R2 = R3 = H) were similarly prepared (R1, m.p., and (or) m.p. of salts given): H, 123° (hexane-C6H6 7:3), oxalate 194° (Me2CO); Et, 90° (heptane), fumarate 200° (EtOH); and Ph-CH2, methanesulfonate 205° (EtOH). IIa (R = Me), m. 196°, IIa (R = PhCH2), m. 202°, IIa (R = H), m. 168°, and IIa (R = Et), m. 207°, were prepared from the corresponding II, m. 104°, 147° (Ger. 1,142,870), 141°, and 120°, resp. II (R = H) was prepared from 10-methoxydibenz[b,f]azepine (IV), m. 125° (Swiss 375,721), and II (R = Et) from 5-ethyl-10-methoxydibenz[b,f]azepine, m. 180°, prepared from IV. I (R1 = R2 = R3 = Me) (V), 6.3 g., m. 65-6° (aqueous EtOH), was prepared from 6.7 g. III in 360 ml. EtOH by reaction with 40 g. 30% aqueous CH2O and H in the presence of 18 g. Raney Ni. To prepare I (R1 = R2 = Me, R3 = H) (VI), 2.25 g. III was heated 2 hrs. with 14.8 g. HCO2Et in an autoclave at 80° to give 2 g. I (R1 = Me, R2 = HCO, R3 = H) (VII), m. 142°, which was added in portions to 1.1 g. LiAlH4 in 180 ml. Et2O; the mixture was refluxed 5 hrs. and worked up to give 1.9 g. VI.HCl, m. 238-40°. The following I were similarly prepared: I (R1 = Me, R2 = Et, R3 = H) (VIII), fumarate m. 135-8° (EtOH), methanesulfonate m. 196°, from I (R1 = Me, R2 = Ac, R3 = H), m. 187°; I (R1 = Me, R2 = R3 = Et), m. 70° (petr. ether), from oily I (R1 = Me, R2 = Et, R3 = Ac), made from VIII; I (R1 = R2 = Me, R3 = Et), maleate m. 135° (AcOEt), from oily I (R1 = Me, R2 = HCO, R3 = Et), made from VIII. V was also prepared from VI with Me2SO4, and by LiAlH4-reduction of I

(R1

= R2 = Me, R3 = EtO2C), b0.1 172-5°, made from VI. VI was also prepared with KOH from I (R1 = R2 = Me, R3 = CN), m. 85-7°; with KOH from I (R1 = R2 = Me, R3 = HCO), m. 95°, made from VII with Me2SO4; and with Na from I (R1 = R2 = Me, R3 = p-MeC6H4SO2), m. 182-3°, prepared from I (R1 = Me, R2 = H, R3 = p-MeC6H4SO2), m. 158°, which was made from III. The title compds., especially VI, act on the central

nervous

system as antidepressants, analgesics, anticonvulsants, and tranquilizers. They are given in doses of 5-50 mg./kg. animal weight, or 10-250 mg. daily to adult humans.

IT 21730-17-6P 21730-20-1P 21737-56-4P


21737-68-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 21730-17-6 CAPLUS

CN Formamide, N-(10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)-N-methyl- (CA INDEX NAME)



RN 21730-20-1 CAPLUS


CN 5H-Dibenz[b,f]azepine-10-carbamic acid, 10,11-dihydro-N,5-dimethyl-, ethyl ester (8CI) (CA INDEX NAME)



RN 21737-56-4 CAPLUS


CN Formamide, N-(10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)- (CA INDEX NAME)

10/574,649



RN 21737-68-8 CAPLUS

CN Acetamide, N-(10,11-dihydro-5-methyl-5H-dibenz[b,f]azepin-10-yl)- (CA
INDEX NAME)



L27 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:11309 CAPLUS

DOCUMENT NUMBER: 144:108328

TITLE: Preparation of benzo[blazepines and related compounds as inhibitors of cholesterol ester transfer protein for treating dyslipidemia

INVENTOR(S): Chen, Xinchao; Cioffi, Christopher Lawrence; Dinn, Sean Richard; Escribano, Ana Maria; Fernandez, Maria Carmen; Fields, Todd; Herr, Robert Jason; Mantlo, Nathan Bryan; De la Nava, Eva Maria Martin; Mateo-Herranz, Ana Isabel; Parthasarathy, Saravanan; Wang, Xiaodong

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 298 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002342	A1	20060105	WO 2005-US22389	20050623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005267436	A1	20060202	AU 2005-267436	20050622
AU 2005258241	A1	20060105	AU 2005-258241	20050623
CA 2570673	A1	20060105	CA 2005-2570673	20050623
EP 1761522	A1	20070314	EP 2005-763328	20050623
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1972932	A	20070530	CN 2005-80020685	20050623
JP 20080504277	T	20080214	JP 2007-518296	20050623
BR 2005012516	A	20080311	BR 2005-12516	20050623
IN 2006KN03401	A	20070615	IN 2006-KN3401	20061117
US 20070244095	A1	20071018	US 2006-570542	20061213
MX 2006014706	A	20070312	MX 2006-14706	20061214
KR 2007031950	A	20070320	KR 2006-727076	20061222
KR 859223	B1	20080918		
NO 2007000470	A	20070326	NO 2007-470	20070124
PRIORITY APPLN. INFO.:			US 2004-582708P	P 20040624
			US 2004-627241P	P 20041112
			US 2005-664862P	P 20050324
			WO 2005-US22389	W 20050623

OTHER SOURCE(S): CASREACT 144:108328; MARPAT 144:108328

GI




AB Benzo[b]azepines and related compds. (shown as I; variables defined below; e.g. [3,5-bis(trifluoromethyl)benzyl][(S)-1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl](2-methyl-2H-tetrazol-5-yl)amine (shown as II)) and their pharmaceutical compns. and methods of use are disclosed. Although the methods of preparation are not claimed, preps. and/or characterization data for .apprx.200 examples of I are included. For example, II was prepared in 19 steps (>99, 95, 99, 92, >99, 96, 83, 87, 80, 63, 76, 85, >99, 98, >99, >99, 95 and 70% yields, resp.) starting with preparation of Me 2-nitro-4-trifluoromethylbenzoate from the acid. For I: n = 0-3; m = 0-3; p is 1 or 2; q is 0-4; Y is a bond, C:O, or S(O)t; wherein t = 0-2; R¹ = hydroxy, C1-C6 alkyl, aryl, C2-C6 alkenyl, C1-C6 haloalkyl, et al.; each R² is bound only to a C atom and is H, hydroxy, halogen, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, et al.; R^{3a} and R^{3b} = H, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, and C1-C6 haloalkyl; R⁴ = -NR^{4a}R^{4b} wherein R^{4a} is a heterocyclic, C1-C6 alkylheterocyclic, or C2-C6 alkenylheterocyclic group; and R^{4b} = C1-C6 alkylaryl, C2-C6 alkenylaryl, C2-C6 alkynylaryl, C1-C6 alkylheterocyclic, C2-C6 alkenylheterocyclic, C1-C6 alkylcycloalkyl, et al.; R⁵ = H, hydroxy, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, aryloxy, et al.; R⁶ = H, C1-C6 alkyl, C2-C6 alkenyl, hydroxy, COR⁷, C1-C6 alkoxy, aryloxy, -OC₂-C₆ alkenyl, -OC₁-C₆ haloalkyl, C1-C6 alkylNR⁷R⁸, C3-C₈ cycloalkyl, heterocyclic, aryl, C1-C6 alkyl-O-C(O)NR⁷R⁸, C1-C6 alkyl-NR⁷C(O)NR⁷R⁸ and C1-C6 alkylcycloalkyl; addnl. details including provisos are given in the claims. The ability of 37 examples of I to elevate HDL cholesterol levels was determined

IT 851045-27-7P 851045-28-8P 851045-32-4P
851045-33-5P 851045-41-5P,
8-Bromo-9-methyl-5-oxo-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid
isopropyl ester 851045-84-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of benzo[b]azepines and related compds. as inhibitors of

cholesterol ester transfer protein for treating dyslipidemia)


RN 851045-27-7 CAPLUS

CN Indeno[5,6-b]azepine-1(2H)-carboxylic acid, 3,4,5,7,8,9-hexahydro-5-oxo-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-28-8 CAPLUS

CN Indeno[5,6-b]azepine-1(2H)-carboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3,4,5,7,8,9-hexahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-32-4 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid, 3,4,5,8,9,10-hexahydro-5-oxo-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-33-5 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3,4,5,8,9,10-hexahydro-,
1-methylethyl ester (CA INDEX NAME)



RN 851045-41-5 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
8-bromo-2,3,4,5-tetrahydro-9-methyl-5-oxo-, 1-methylethyl ester (CA INDEX
NAME)



10/574,649

RN 851045-84-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:371225 CAPLUS

DOCUMENT NUMBER: 142:430156

TITLE: Preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia

INVENTOR(S): Cao, Guoqing; Escribano, Ana Maria; Fernandez, Maria Carmen; Fields, Todd; Gernert, Douglas Linn; Cioffi, Christopher Lawrence; Herr, Robert Jason; Mantlo, Nathan Bryan; Martin De La Nava, Eva Maria; Mateo Herranz, Ana Isabel; Mayhugh, Daniel Ray; Wang, Xiaodong

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 188 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037796	A1	20050428	WO 2004-US30907	20041007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004282101	A1	20050428	AU 2004-282101	20041007
CA 2537942	A1	20050428	CA 2004-2537942	20041007
EP 1670768	A1	20060621	EP 2004-793889	20041007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014186	A	20061031	BR 2004-14186	20041007
CN 1863778	A	20061115	CN 2004-80029540	20041007
JP 2007508301	T	20070405	JP 2006-533949	20041007
IN 2006KN00372	A	20070316	IN 2006-KN372	20060220
US 20070254869	A1	20071101	US 2006-574649	20060330
KR 2006085675	A	20060727	KR 2006-706837	20060407
MX 2006003927	A	20080207	MX 2006-3927	20060407
NO 2006002074	A	20060508	NO 2006-2074	20060508
PRIORITY APPLN. INFO.:			US 2003-509736P	P 20031008
			WO 2004-US30907	W 20041007
OTHER SOURCE(S):		CASREACT 142:430156; MARPAT 142:430156		
GI				



AB Title compds. I [n, m, q = 0-3; p = 1-2; R1 = OH, alkyl, aryl, etc.; R2 = H, OH, halo, etc.; R3 = H; R4 = (un)substituted amino; R5 = H, OH, halo, etc.; R6 = allyl alc., alkoxy, etc.] are prepared For instance, 5-[acetyl(3,5-bis(trifluoromethyl)benzyl)amino]-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid iso-Pr ester (II) is prepared in 8 steps from 2-aminobenzoic acid Me ester, Et 4-bromobutyrate and 3,5-bis(trifluoromethyl)benzylamine. II has an IC50 of 293 nM for cholesterol ester transfer protein (CETP). I are useful for treating atherosclerosis and its sequelae.


IT 1044022-86-7

RL: PRPH (Prophetic)

(Preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 1044022-86-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(2-ethylhydrazinyl)-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



IT 851044-03-6P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851044-03-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1-methylethyl ester, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 851043-54-4P 851043-55-5P 851043-97-5P

851043-98-6P 851044-04-7P 851044-11-6P

851044-12-7P 851044-75-2P 851044-76-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)

(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851043-54-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851043-55-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851043-97-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-7-methyl-, 1-methylethyl ester, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851043-98-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851044-04-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1-methylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,649



RN 851044-11-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(1,1-dimethylethyl)amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5R)- (CA INDEX
NAME)

Absolute stereochemistry.




RN 851044-12-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(1,1-dimethylethyl)amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5S)- (CA INDEX
NAME)

Absolute stereochemistry.


10/574,649



RN 851044-75-2 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-3,4,5,8,9,10-
hexahydro-, 1-methylethyl ester, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851044-76-3 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-3,4,5,8,9,10-
hexahydro-, 1-methylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 851042-69-8P 851042-71-2P 851042-85-8P
 851042-92-7P 851043-04-4P 851043-05-5P
 851043-08-8P 851043-13-5P 851043-24-8P
 851043-26-0P 851043-34-0P 851043-39-5P
 851043-46-4P 851043-50-0P 851043-83-9P
 851043-95-3P 851043-96-4P 851044-00-3P
 851044-02-5P 851044-05-8P 851044-07-0P
 851044-09-2P 851044-10-5P 851044-21-8P
 851044-23-0P 851044-31-0P 851044-32-1P
 851044-74-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851042-69-8 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-71-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-85-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-
 [(diphenylmethylene)amino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA
 INDEX NAME)




RN 851042-92-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-amino-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-04-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-bromo-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-05-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-fluoro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-08-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-amino-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-13-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-24-8 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-(methylthio)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-26-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-(phenylmethoxy)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-34-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
 tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-39-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-8-fluoro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-46-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-bromo-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-50-0 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-bromo-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-83-9 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-difluorophenyl)methyl]amino]-8-chloro-2,3,4,5-tetrahydro-,
1-methylethyl ester (CA INDEX NAME)



RN 851043-95-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-8-chloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-96-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-00-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-02-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-05-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-amino-2,3,4,5-
tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-07-0 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-ethenyl-2,3,4,5-
tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-09-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-10-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-21-8 CAPLUS
 CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3,4,5,8,9,10-
 hexahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-23-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-bromo-2,3,4,5-
 tetrahydro-9-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-31-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(1,1-dimethylethyl)amino]-2,3,4,5-tetrahydro-
 7-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-32-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(1,1-dimethylethyl)amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851044-74-1 CAPLUS

CN 5H-1,3-Dioxolo[4,5-h][1]benzazepine-5-carboxylic acid,
 9-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,2-difluoro-
 6,7,8,9-tetrahydro-, 1,1-dimethylethyl ester, (9S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 851042-67-6P 851042-68-7P 851042-70-1P
 851042-72-3P 851042-73-4P 851042-74-5P
 851042-75-6P 851042-76-7P 851042-77-8P
 851042-78-9P 851042-79-0P 851042-80-3P
 851042-81-4P 851042-82-5P 851042-83-6P
 851042-84-7P 851042-86-9P 851042-87-0P
 851042-88-1P 851042-89-2P 851042-90-5P
 851042-91-6P 851042-93-8P 851042-94-9P
 851042-95-0P 851042-96-1P 851042-97-2P


851042-98-3P 851042-99-4P 851043-00-0P
 851043-01-1P 851043-02-2P 851043-03-3P
 851043-06-6P 851043-07-7P 851043-09-9P
 851043-10-2P 851043-11-3P 851043-12-4P
 851043-14-6P 851043-15-7P 851043-16-8P
 851043-17-9P 851043-18-0P 851043-19-1P
 851043-20-4P 851043-21-5P 851043-22-6P
 851043-23-7P 851043-25-9P 851043-27-1P
 851043-28-2P 851043-29-3P 851043-30-6P
 851043-31-7P 851043-32-8P 851043-33-9P
 851043-35-1P 851043-36-2P 851043-37-3P
 851043-38-4P 851043-40-8P 851043-41-9P
 851043-42-0P 851043-43-1P 851043-44-2P
 851043-45-3P 851043-47-5P 851043-48-6P
 851043-49-7P 851043-51-1P 851043-52-2P
 851043-53-3P 851043-56-6P 851043-57-7P
 851043-58-8P 851043-59-9P 851043-61-3P
 851043-63-5P 851043-65-7P 851043-67-9P
 851043-69-1P 851043-71-5P 851043-73-7P
 851043-75-9P 851043-77-1P 851043-79-3P
 851043-80-6P 851043-81-7P 851043-82-8P
 851043-84-0P 851043-85-1P 851043-86-2P
 851043-87-3P 851043-88-4P 851043-89-5P
 851043-90-8P 851043-91-9P 851043-92-0P
 851043-93-1P 851043-94-2P 851043-99-7P
 851044-01-4P 851044-06-9P 851044-08-1P
 851044-13-8P 851044-14-9P 851044-15-0P
 851044-16-1P 851044-17-2P 851044-18-3P
 851044-19-4P 851044-20-7P 851044-22-9P
 851044-24-1P 851044-25-2P 851044-26-3P
 851044-27-4P 851044-28-5P 851044-29-6P
 851044-30-9P 851044-33-2P 851044-34-3P
 851044-35-4P 851044-36-5P 851044-37-6P
 851044-38-7P 851044-39-8P 851044-40-1P
 851044-41-2P 851044-42-3P 851044-43-4P
 851044-44-5P 851044-45-6P 851044-46-7P
 851044-47-8P 851044-48-9P 851044-49-0P
 851044-50-3P 851044-51-4P 851044-52-5P
 851044-53-6P 851044-54-7P 851044-55-8P
 851044-56-9P 851044-57-0P 851044-58-1P
 851044-59-2P 851044-60-5P 851044-61-6P
 851044-62-7P 851044-63-8P 851044-64-9P
 851044-65-0P 851044-66-1P 851044-67-2P
 851044-68-3P 851044-69-4P 851044-70-7P
 851044-71-8P 851044-72-9P 851044-73-0P
 851044-77-4P 851044-78-5P 851044-79-6P
 851044-80-9P 851044-81-0P 851044-82-1P
 851044-83-2P 851044-84-3P 851044-85-4P
 851044-86-5P 851044-87-6P 851044-88-7P
 851044-89-8P 851044-90-1P 851044-91-2P
 851044-92-3P 851044-93-4P 851044-94-5P
 851044-95-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzazepines as inhibitors of cholesterol ester transfer
 protein for treating dyslipidemia)


RN 851042-67-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
1-methylethyl ester (CA INDEX NAME)




RN 851042-68-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-70-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-8-
chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-72-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-(trifluoromethoxy)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-73-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-74-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-(4-methylphenyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-75-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(4-chlorophenyl)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851042-76-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-(4-methoxyphenyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-77-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(4-fluorophenyl)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-78-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(2-fluorophenyl)-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-79-0 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-[2-(trifluoromethyl)phenyl]-, 1-methylethyl ester (CA INDEX NAME)



RN 851042-80-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-(2-methylphenyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-81-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-phenyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-82-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-[4-(trifluoromethyl)phenyl]-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-83-6 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-(4-morpholinyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-84-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-(4-methyl-1-piperazinyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-86-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-(phenylamino)-, 1-methylethyl ester (CA INDEX NAME)



RN 851042-87-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-(1-pyrrolidinyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-88-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-(2-oxo-1-azetidiny)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-89-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
7-(2-oxo-1-pyrrolidinyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-90-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-(1-azetidiny)-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-91-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-93-8 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(dimethylamino)-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-94-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-[(methylsulfonyl)amino]-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-95-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 7-(acetylamino)-5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851042-96-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-[(phenylsulfonyl)amino]-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-97-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(benzoylamino)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-98-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-ethenyl-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-99-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
7-acetyl-5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-00-0 CAPLUS
 CN 1H-1-Benzazepine-1,7-dicarboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 , 7-methyl 1-(1-methylethyl) ester (CA INDEX NAME)




RN 851043-01-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-formyl-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-02-2 CAPLUS
 CN 1H-1-Benzazepine-1,7-dicarboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 , 1-(1-methylethyl) ester (CA INDEX NAME)




RN 851043-03-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-fluoro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-06-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-phenyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-07-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-cyano-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-09-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-[(methylsulfonyl)amino]-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-10-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 8-(acetylamino)-5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-11-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-[(phenylsulfonyl)amino]-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-12-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(benzoylamino)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-14-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-ethenyl-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-15-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-ethyl-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-16-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(dimethylamino)-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-17-9 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(diethylamino)-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-18-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-(hydroxymethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-19-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-(4-morpholinyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-20-4 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-(1-pyrrolidinyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-21-5 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(ethylamino)-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-22-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(1-azetidiny)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-23-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-methoxy-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-25-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-(methylsulfonyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-27-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-hydroxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-28-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-bromo-2,3,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851043-29-3 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851043-30-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-7-cyano-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-31-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7,8-dichloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-32-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-7-
 (dimethylamino)-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-33-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-7-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-35-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-chloro-2,3,4,5-
 tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-36-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-amino-2,3,4,5-
 tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-37-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(dimethylamino)-
 2,3,4,5-tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-38-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7,8-dimethyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-40-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-fluoro-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-41-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7,8-dimethoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-42-0 CAPLUS

CN 1H-Naphth[2,3-b]azepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
1-methylethyl ester (CA INDEX NAME)




RN 851043-43-1 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
9-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-44-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 9-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-45-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-47-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
9-(trifluoromethoxy)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-48-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-amino-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-49-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-(dimethylamino)-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-51-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-amino-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-52-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-(dimethylamino)-
2,3,4,5-tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-53-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7,9-dimethyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-56-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-57-7 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2,3,4,5-
tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-58-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
 8-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




RN 851043-59-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 851043-61-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](1-oxopropyl)amino]-8-chloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-63-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2,2,2-trifluoroacetyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-65-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](ethoxycarbonyl)amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-67-9 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(1-
methylethoxy)carbonyl]amino]-8-chloro-2,3,4,5-tetrahydro-, 1-methylethyl
ester (CA INDEX NAME)



RN 851043-69-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (ethylamino)carbonyl]amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-71-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(4-fluorophenyl)methyl]amino]-8-chloro-2,3,4,5-tetrahydro-,
 1-methylethyl ester (CA INDEX NAME)




RN 851043-73-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[4-(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-75-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[4-(trifluoromethoxy)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-77-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3-(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-79-3 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-dimethoxyphenyl)methyl]amino]-8-chloro-2,3,4,5-tetrahydro-,
1-methylethyl ester (CA INDEX NAME)




RN 851043-80-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-dibromophenyl)methyl]amino]-8-chloro-2,3,4,5-tetrahydro-,
 1-methylethyl ester (CA INDEX NAME)




RN 851043-81-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-dimethylphenyl)methyl]amino]-8-chloro-2,3,4,5-tetrahydro-,
 1-methylethyl ester (CA INDEX NAME)



RN 851043-82-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-dichlorophenyl)methyl]amino]-8-chloro-2,3,4,5-tetrahydro-,
 1-methylethyl ester (CA INDEX NAME)




RN 851043-84-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3-fluoro-5-(trifluoromethyl)phenyl)methyl]amino]-8-chloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-85-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(2,4-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-86-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[4-fluoro-2-(trifluoromethyl)phenyl)methyl]amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-87-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-88-4 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-89-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-90-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[4-chloro-3-(trifluoromethyl)phenyl]methyl]amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-91-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[2-chloro-5-(trifluoromethyl)phenyl]methyl]amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-92-0 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-93-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(5-fluoro-2-(trifluoromethyl)phenyl)methyl]amino]-8-chloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-94-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, phenylmethyl ester (CA INDEX NAME)




RN 851043-99-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-7-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-01-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-chloro-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-06-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(dimethylamino)-
 2,3,4,5-tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX
 NAME)




RN 851044-08-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-ethyl-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-13-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, tetrahydro-2H-pyran-4-yl ester, (5S)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 851044-14-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, cyclobutyl ester, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851044-15-0 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, cyclopentyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851044-16-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
7,9-dimethyl-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-17-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-6-fluoro-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-18-3 CAPLUS


CN Indeno[5,6-b]azepine-1(2H)-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-3,4,5,7,8,9-
hexahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-19-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]formylamino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-20-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]ethylamino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-22-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 6-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-24-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-9-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-25-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8,9-dimethyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-26-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-6-fluoro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-27-4 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
9-methyl-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-28-5 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-
3,4,5,8,9,10-hexahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-29-6 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-3,4,5,8,9,10-
hexahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-30-9 CAPLUS

CN Indeno[5,6-b]azepine-1(2H)-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-3,4,5,7,8,9-
hexahydro-10-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-33-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](1-oxopropyl)amino]-8-chloro-
2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-34-3 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](3-methyl-1-oxobutyl)amino]-8-
chloro-2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-35-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](cyclopropylcarbonyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-36-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](cyclopentylcarbonyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-37-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[benzoyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851044-38-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methoxyacetyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-39-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-furanylcarbonyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-40-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, cyclopentyl ester (CA INDEX NAME)

10/574,649




RN 851044-41-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, cyclobutyl ester (CA INDEX NAME)




RN 851044-42-3 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, cyclohexyl ester (CA INDEX NAME)



RN 851044-43-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-ethylpropyl ester (CA INDEX NAME)




RN 851044-44-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 2-methyl-1-(1-methylethyl)propyl ester (CA INDEX NAME)




RN 851044-45-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1,2-dimethylpropyl ester (CA INDEX NAME)




RN 851044-46-7 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-ethyl-2-methylpropyl ester (CA INDEX NAME)



RN 851044-47-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 2,2,2-trifluoro-1-methylethyl ester (CA INDEX NAME)




RN 851044-48-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylpropyl ester (CA INDEX NAME)



RN 851044-49-0 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 3-methylcyclopentyl ester (CA INDEX NAME)

PAGE 1-A




Me

RN 851044-50-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-(methoxymethyl)propyl ester (CA INDEX NAME)



RN 851044-51-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, tetrahydro-1,1-dioxido-3-thienyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 851044-52-5 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, (tetrahydro-3-furanyl)methyl ester (CA INDEX NAME)



RN 851044-53-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methylamino]-8-chloro-2,3,4,5-
tetrahydro-, (3S)-tetrahydro-3-furanyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 851044-54-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, (3R)-tetrahydro-3-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 851044-55-8 CAPLUS

CN 1H-1-Benzazepine-1-carbothioic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, S-(1-methylethyl) ester (CA INDEX NAME)


RN 851044-56-9 CAPLUS

CN Acetamide, N-(1-acetyl-8-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl)-N-
[[3,5-bis(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 851044-57-0 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(2-methyl-1-oxopropyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-58-1 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(1-oxopropyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-59-2 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(2-methyl-1-oxobutyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-60-5 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(3-methyl-1-oxobutyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)



RN 851044-61-6 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-1-(2-ethyl-1-oxobutyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)



RN 851044-62-7 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-1-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)

10/574,649



RN 851044-63-8 CAPLUS


CN Acetamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-N-[8-chloro-1-(cyclopentylcarbonyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)



RN 851044-64-9 CAPLUS


CN Acetamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-N-[8-chloro-1-(cyclohexylcarbonyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)

10/574,649




RN 851044-65-0 CAPLUS

CN Acetamide, N-(1-benzoyl-8-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 851044-66-1 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(2-methoxyacetyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-67-2 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(3-methyl-1-oxo-2-buten-1-yl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-68-3 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-1-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-69-4 CAPLUS

CN 1H-1-Benzazepine-1-carboxamide, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-tetrahydro-N-(1-methylethyl)- (CA INDEX NAME)




RN 851044-70-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxamide, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-N-(1,1-dimethylethyl)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 851044-71-8 CAPLUS


CN 1H-1-Benzazepine-1-carboxamide, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-N,N-diethyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 851044-72-9 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(1-pyrrolidinylcarbonyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)

10/574,649




RN 851044-73-0 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(1-[3,5-bis(trifluoromethyl)phenyl]methylamino)-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethoxy)-, cyclopentyl ester (CA INDEX NAME)




RN 851044-77-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(1-[3,5-bis(trifluoromethyl)phenyl]methylamino)-2,3,4,5-tetrahydro-
7-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-78-5 CAPLUS
 CN 1-Benzazocine-1(2H)-carboxylic acid,
 6-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-bromo-3,4,5,6-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-79-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methylsulfonyl)amino]-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-80-9 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[2,3,4,5-tetrahydro-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-81-0 CAPLUS

CN Carbamic acid, [[3,5-bis(trifluoromethyl)phenyl]methyl][2,3,4,5-tetrahydro-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 851044-82-1 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-1-(5-ethoxy-1,3,4-oxadiazol-2-yl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)



RN 851044-83-2 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(5-phenyl-1,3,4-oxadiazol-2-yl)-1H-1-benzazepin-5-yl]- (CA

INDEX NAME)



RN 851044-84-3 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-[4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]-1H-1-benzazepin-5-yl]- (CA INDEX NAME)



RN 851044-85-4 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(5-methyl-1H-pyrazol-3-yl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)

10/574,649




RN 851044-86-5 CAPLUS

CN Acetamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-N-[8-chloro-2,3,4,5-tetrahydro-1-(3-methyl-5-isoxazolyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851044-87-6 CAPLUS

CN Acetamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-N-[8-chloro-2,3,4,5-tetrahydro-1-(2-methyl-2H-tetrazol-5-yl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)



RN 851044-88-7 CAPLUS


CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl)methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)



RN 851044-89-8 CAPLUS


CN 1H-1-Benzazepine-1-carboxamide, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-tetrahydro-N-(methylsulfonyl)- (CA INDEX NAME)


10/574,649



RN 851044-90-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxamide, 5-[acetyl[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)


PAGE 1-A





RN 851044-91-2 CAPLUS
 CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[(5S)-1-(cyclopentylmethyl)-2,3,4,5-tetrahydro-7-methyl-8-(trifluoromethyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 851044-92-3 CAPLUS
 CN 1H-1-Benzazepine-1-pentanoic acid, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-β,β,7-trimethyl-8-(trifluoromethyl)-, methyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.

10/574,649




RN 851044-93-4 CAPLUS
 CN 1H-Naphth[2,3-b]azepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5,7,8,9,10-
 octahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-94-5 CAPLUS
 CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[(9S)-5-
 (cyclopentylmethyl)-2,2-difluoro-6,7,8,9-tetrahydro-5H-1,3-dioxolo[4,5-
 h][1]benzazepin-9-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 851044-95-6 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[1-(cyclopentylmethyl)-2,3,4,5,7,9-hexahydro-1H-furo[3,4-h]-1-benzazepin-5-yl]- (CA INDEX NAME)




IT 851045-84-6 851045-85-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851045-84-6 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851045-85-7 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[(5S)-2,3,4,5-tetrahydro-7-methyl-8-(trifluoromethyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 116815-03-3P 851044-96-7P 851044-97-8P
 851045-00-6P 851045-01-7P 851045-02-8P
 851045-03-9P 851045-04-0P 851045-05-1P
 851045-06-2P 851045-07-3P 851045-08-4P
 851045-11-9P 851045-12-0P 851045-13-1P
 851045-14-2P 851045-15-3P 851045-16-4P
 851045-17-5P 851045-22-2P 851045-23-3P
 851045-24-4P 851045-25-5P 851045-27-7P
 851045-28-8P 851045-32-4P 851045-33-5P
 851045-36-8P 851045-37-9P 851045-41-5P
 851045-42-6P 851045-43-7P 851045-46-0P


851045-47-1P 851045-48-2P 851045-54-0P
 851045-55-1P 851045-56-2P 851045-59-5P
 851045-60-8P 851045-61-9P 851045-62-0P
 851045-69-7P 851045-70-0P 851045-71-1P
 851045-72-2P 851045-75-5P 851045-76-6P
 851045-77-7P 851045-78-8P 851045-79-9P
 851045-80-2P 851045-81-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of benzazepines as inhibitors of cholesterol ester transfer
 protein for treating dyslipidemia)


RN 116815-03-3 CAPLUS

CN 5H-1-Benzazepin-5-one, 8-chloro-1,2,3,4-tetrahydro- (CA INDEX NAME)




RN 851044-96-7 CAPLUS

CN 1H-1-Benzazepine-4-carboxylic acid,
 2,3,4,5-tetrahydro-1-[(4-methylphenyl)sulfonyl]-5-oxo-, methyl ester (CA
 INDEX NAME)




RN 851044-97-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid, 2,3,4,5-tetrahydro-5-oxo-,
 1-methylethyl ester (CA INDEX NAME)




RN 851045-00-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid, 8-bromo-2,3,4,5-tetrahydro-5-oxo-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-01-7 CAPLUS

CN 1H-1-Benzazepine-1,4-dicarboxylic acid, 8-bromo-2,3,4,5-tetrahydro-5-oxo-, 4-methyl 1-(1-methylethyl) ester (CA INDEX NAME)




RN 851045-02-8 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-[(diphenylmethylene)amino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-03-9 CAPLUS
 CN 5H-1-Benzazepin-5-one, 8-bromo-1,2,3,4-tetrahydro- (CA INDEX NAME)



RN 851045-04-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid, 8-bromo-2,3,4,5-tetrahydro-5-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851045-05-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid, 8-chloro-2,3,4,5-tetrahydro-5-oxo-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-06-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
8-chloro-2,3,4,5-tetrahydro-5-(hydroxyimino)-, 1-methylethyl ester (CA
INDEX NAME)



RN 851045-07-3 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid, 5-amino-8-chloro-2,3,4,5-tetrahydro-,
1-methylethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 851045-08-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
8-chloro-5-[(4-fluorophenyl)methyl]amino]-2,3,4,5-tetrahydro-,
1-methylethyl ester (CA INDEX NAME)



RN 851045-11-9 CAPLUS
 CN 1H-1-Benzazepine-1,4-dicarboxylic acid,
 7-bromo-8-chloro-2,3,4,5-tetrahydro-5-oxo-, 4-methyl 1-(1-methylethyl)
 ester (CA INDEX NAME)




RN 851045-12-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 7-bromo-8-chloro-2,3,4,5-tetrahydro-5-oxo-, 1-methylethyl ester (CA INDEX
 NAME)




RN 851045-13-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-bromo-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-14-2 CAPLUS

CN Acetamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[2,3,4,5-
tetrahydro-7-methyl-8-(trifluoromethyl)-1H-1-benzazepin-5-yl]]- (CA INDEX
NAME)




RN 851045-15-3 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[2,3,4,5-tetrahydro-7-(trifluoromethyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851045-16-4 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[9-bromo-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851045-17-5 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[2,3,4,5-tetrahydro-9-methyl-7-(trifluoromethyl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851045-22-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid, 6-fluoro-2,3,4,5-tetrahydro-7-methyl-5-oxo-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-23-3 CAPLUS

CN 1H-1-Benzazepine-1,4-dicarboxylic acid,
6-fluoro-2,3,4,5-tetrahydro-7-methyl-5-oxo-, 4-methyl 1-(1-methylethyl)
ester (CA INDEX NAME)




RN 851045-24-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6-fluoro-2,3-dihydro-7-
methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851045-25-5 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6-fluoro-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)

RN 851045-27-7 CAPLUS

CN Indeno[5,6-b]azepine-1(2H)-carboxylic acid, 3,4,5,7,8,9-hexahydro-5-oxo-,
1-methylethyl ester (CA INDEX NAME)


RN 851045-28-8 CAPLUS

CN Indeno[5,6-b]azepine-1(2H)-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3,4,5,7,8,9-hexahydro-,
1-methylethyl ester (CA INDEX NAME)




RN 851045-32-4 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid, 3,4,5,8,9,10-hexahydro-5-oxo-,
1-methylethyl ester (CA INDEX NAME)




RN 851045-33-5 CAPLUS

CN Indeno[4,5-b]azepine-1(2H)-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3,4,5,8,9,10-hexahydro-,
1-methylethyl ester (CA INDEX NAME)




RN 851045-36-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid, 2,3,4,5-tetrahydro-6-methyl-5-oxo-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-37-9 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-6-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851045-41-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 8-bromo-2,3,4,5-tetrahydro-9-methyl-5-oxo-, 1-methylethyl ester (CA INDEX
 NAME)




RN 851045-42-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 8-chloro-2,3,4,5-tetrahydro-9-methyl-5-oxo-, 1-methylethyl ester (CA
 INDEX NAME)



10/574,649


RN 851045-43-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-9-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-46-0 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid, 6-fluoro-2,3,4,5-tetrahydro-5-oxo-,
1-methylethyl ester (CA INDEX NAME)




RN 851045-47-1 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6-fluoro-2,3-dihydro-,
1-methylethyl ester (CA INDEX NAME)




RN 851045-48-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6-fluoro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-54-0 CAPLUS
 CN 5H-1-Benzazepin-5-one, 1,2,3,4-tetrahydro-7-(trifluoromethyl)- (CA INDEX
 NAME)




RN 851045-55-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 2,3,4,5-tetrahydro-5-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester
 (CA INDEX NAME)




RN 851045-56-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-7-
 (trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851045-59-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid, 8-chloro-2,3,4,5-tetrahydro-5-oxo-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851045-60-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851045-61-9 CAPLUS
 CN Acetamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-(8-chloro-2,3,4,5-
 tetrahydro-1H-1-benzazepin-5-yl)- (CA INDEX NAME)



RN 851045-62-0 CAPLUS
 CN 1H-1-Benzazepine-1-carbonyl chloride,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro- (CA INDEX NAME)




RN 851045-69-7 CAPLUS
 CN 5H-1-Benzazepin-5-one, 1,2,3,4-tetrahydro-7-methyl-8-(trifluoromethoxy)-
 (CA INDEX NAME)



10/574,649

RN 851045-70-0 CAPLUS


CN 5H-1,3-Dioxolo[4,5-h][1]benzazepine-5-carboxylic acid,
2,2-difluoro-6,7,8,9-tetrahydro-9-oxo-, 1,1-dimethylethyl ester (CA INDEX
NAME)



RN 851045-71-1 CAPLUS

CN 5H-1,3-Dioxolo[4,5-h][1]benzazepine-5-carboxylic acid,
2,2-difluoro-6,7,8,9-tetrahydro-9-hydroxy-, 1,1-dimethylethyl ester, (9R)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 851045-72-2 CAPLUS

CN 5H-1,3-Dioxolo[4,5-h][1]benzazepine-5-carboxylic acid,
9-[[[3,5-bis(trifluoromethyl)phenyl]methylamino]-2,2-difluoro-6,7,8,9-
tetrahydro-, 1,1-dimethylethyl ester, (9S)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,649




RN 851045-75-5 CAPLUS

CN 1H-1-Benzazepin-5-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-
2,3,4,5-tetrahydro-1-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 851045-76-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, hydrazide (CA INDEX NAME)




RN 851045-77-7 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-1-(1,3-dioxobutyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851045-78-8 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-(8-chloro-1-cyano-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl)- (CA INDEX NAME)




RN 851045-79-9 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[8-chloro-2,3,4,5-tetrahydro-1-(2H-tetrazol-5-yl)-1H-1-benzazepin-5-yl]- (CA INDEX NAME)




RN 851045-80-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxamide, 5-[acetyl([3,5-bis(trifluoromethyl)phenyl]methyl)amino]-8-chloro-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 851045-81-3 CAPLUS
 CN 1H-furo[3,4-h]-1-benzazepine-1-carboxylic acid,
 2,3,4,5,7,9-hexahydro-5-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 1001387-85-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of benzazepines as inhibitors of cholesterol ester transfer
 protein for treating dyslipidemia)
 RN 1001387-85-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
 9-methyl-7-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)

10/574,649




REFERENCE COUNT:

1


THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:228179 CAPLUS
DOCUMENT NUMBER: 133:257
TITLE: Synthesis and diuretic activity of bicyclic fused heterocycles containing oxime-O-sulfonic acid moiety
AUTHOR(S): Nishijima, Kazumi; Nishida, Hidemitsu; Yamashita, Yoshiaki; Ito, Manabu; Onuki, Yoshiaki; Mizota, Masahiro; Miyano, Sotaro
CORPORATE SOURCE: Fuji Central Research Laboratory, Mochida Pharmaceutical Co. Ltd., Shizuoka, 412-8524, Japan
SOURCE: European Journal of Medicinal Chemistry (2000), 35(2), 227-240
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In order to investigate the origin of the loop-type diuretic activity of M17055, several variants were designed and synthesized by modifying the quinolinone skeleton, and their diuretic activities were compared with the lead M17055 and furosemide in dogs. It was found that the neg. charge distribution pattern afforded by the dispositional arrangement of the 4-oxime-O-sulfonic acid and 1-N-acyl carbonyl moiety attached to the tetrahydropyridine ring system is inevitable for the development of the activity, which strongly supports the previously proposed model for the active site of the Na⁺-K⁺-2Cl⁻ cotransporter.
IT 116815-03-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and diuretic activity of bicyclic fused heterocycles containing oxime-O-sulfonic acid moiety)
RN 116815-03-3 CAPLUS
CN 5H-1-Benzazepin-5-one, 8-chloro-1,2,3,4-tetrahydro- (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:571362 CAPLUS
 DOCUMENT NUMBER: 131:322523
 TITLE: 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist
 AUTHOR(S): Kondo, Kazumi; Ogawa, Hidenori; Yamashita, Hiroshi; Miyamoto, Hisashi; Tanaka, Michinori; Nakaya, Kenji; Kitano, Kazuyoshi; Yamamura, Yoshitaka; Nakamura, Shigeki; Onogawa, Toshiyuki; Mori, Toyoki; Tominaga, Michiaki
 CORPORATE SOURCE: Second Tokushima Institute of New Drug Research, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan
 SOURCE: Bioorganic & Medicinal Chemistry (1999), 7(8), 1743-1757
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We previously reported a series of benzazepine derivs. as orally active nonpeptide arginine vasopressin (AVP) V2 receptor antagonists. After the lead structure OPC-31260 was structurally evaluated and optimized, the introduction of the 7-Cl moiety on the benzazepine and 2-CH3 on the aminobenzoyl moiety enhanced its oral activity. The new AVP-V2 selective antagonist OPC-41061 was determined to be a potent and orally active agent.
 IT 116815-03-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and activity of 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061) as an orally active nonpeptide arginine vasopressin V2 receptor antagonist)
 RN 116815-03-3 CAPLUS
 CN 5H-1-Benzazepin-5-one, 8-chloro-1,2,3,4-tetrahydro- (CA INDEX NAME)






REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:483100 CAPLUS
DOCUMENT NUMBER: 121:83100
ORIGINAL REFERENCE NO.: 121:14933a,14936a
TITLE: Conformational and structural features determining in vitro antimalarial activity in some indolo[3,2-c]quinolines, anilinoquinolines and tetrahydroindolo[3,2-d]benzazepines
AUTHOR(S): Koh, H. L.; Go, M. L.; Ngiam, T.I.; Mak, J. W.
CORPORATE SOURCE: Dep. Pharm., Natl. Univ. Singapore, Singapore, 0511, Singapore
SOURCE: European Journal of Medicinal Chemistry (1994), 29(2), 107-13
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of indolo[3,2-c]quinolines, anilinoquinolines and tetrahydroindolo[3,2-d]benzazepines, which differ in the conformational planarity of the key nuclei and the distance (N...N) between the ring and side-chain nitrogen atoms, have been synthesized and evaluated in vitro against a number of isolates of Plasmodium falciparum. The results show that differences in conformational planarity of the indolo[3,2-c]quinoline (rigid), anilinoquinoline (flexible) and tetrahydroindolo[3,2-d]benzazepine (semi-rigid) nuclei have little effect on activity. However, the N...N distance is an important determinant of activity and analogs with a distance comparable to the N...N distance of amodiaquine and chloroquine demonstrated antimalarial activity.
IT 116815-03-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with arylamines)
RN 116815-03-3 CAPLUS
CN 5H-1-Benzazepin-5-one, 8-chloro-1,2,3,4-tetrahydro- (CA INDEX NAME)




L27 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1992:591717 CAPLUS
 DOCUMENT NUMBER: 117:191717
 ORIGINAL REFERENCE NO.: 117:33111a,33114a
 TITLE: Novel synthesis of 10-chloro-3-substituted
 aminomethyl-4-methoxy-6,7-dihydro-8H-indolo[3,2-
 d]benzazepine derivatives
 AUTHOR(S): Ibrahim, E. S. I.; Orabi, M. O. A.; El-Badawy, M.;
 Islam, I.; Proctor, G. R.
 CORPORATE SOURCE: Fac. Sci., Suez Canal Univ., Ismailia, Egypt
 SOURCE: Egyptian Journal of Chemistry (1991), Volume Date
 1989, 32(3), 359-66
 CODEN: EGJCA3; ISSN: 0367-0422
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 117:191717
 GI




AB The title compds. I (R = Me, Et) were prepared by cyclization of benzazepine
 II with hydrazinomethoxydialkylbenzylamines III. II was prepared in several
 steps from Me N-tosyl-4-chloroanthranilate; III was prepared from
 4-nitroanisole.
 IT 116815-03-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclocondensation of, with
 hydrazinomethoxydialkylbenzylamines)
 RN 116815-03-3 CAPLUS
 CN 5H-1-Benzazepin-5-one, 8-chloro-1,2,3,4-tetrahydro- (CA INDEX NAME)

10/574,649



L27 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1988:549388 CAPLUS
 DOCUMENT NUMBER: 109:149388
 ORIGINAL REFERENCE NO.: 109:24847a,24850a
 TITLE: Synthesis of indolo[3,2-c]quinolines and
 indolo[3,2-d]benzazepines and their interaction with
 DNA
 AUTHOR(S): Ibrahim, El Sayed; Montgomerie, Anita M.; Sneddon,
 Andrew H.; Proctor, George R.; Green, Brian
 CORPORATE SOURCE: Dep. Chem. Biochem., Univ. Strathclyde, Glasgow, G1
 1XL, UK
 SOURCE: European Journal of Medicinal Chemistry (1988), 23(2),
 183-8
 CODEN: EJMCA5; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 109:149388
 GI




AB A number of indolo[3,2-c]quinolines, e.g. I (R = H, OMe; R1 = CH2NMe2, CH2Net2, H), and tetrahydroindolo[3,2-d]-1-benzazepines, e.g. II (R, R1 = same), were prepared by Fischer indolization of ketones, including 7-chloro-1,2,3,4-tetrahydroquinol-4-one and 8-chloro-2,3,4,5-tetrahydro-1-benzazepin-5-one, with several hydrazines. Some of the planar indolo[3,2-c]quinoline derivs. form intercalation complexes with DNA and inhibit the synthesis of macromols. in cultured KB cells. Non-planar tetrahydroindolo[3,2-d]-1-benzazepines did not form intercalation complexes with DNA under the same conditions. I (R = OMe, R1 = CH2Net2; R = H, R1 = CH2NMe2) inhibited the synthesis of macromols. in cultured KB cells, I (R = OMe, R1 = CH2Net2) being the most effective. No significant anti-tumor activity was detected for I or II in the NIH screening program.

IT 116815-03-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclocondensation reaction of, with phenylhydrazines, indolobenzazepines from)


RN 116815-03-3 CAPLUS
 CN 5H-1-Benzazepin-5-one, 8-chloro-1,2,3,4-tetrahydro- (CA INDEX NAME)

10/574,649



10/574,649


L5 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 936333-23-2 REGISTRY
ED Entered STN: 01 Jun 2007
CN Benzamide, N-[2,3,4,5-tetrahydro-1-(phenylmethyl)-1H-1-benzazepin-5-yl]-
(CA INDEX NAME)
MF C24 H24 N2 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,649


L5 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 936333-29-8 REGISTRY
ED Entered STN: 01 Jun 2007
CN Benzamide, N-[1-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]- (CA INDEX NAME)
MF C24 H30 N2 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,649


L5 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 936333-27-6 REGISTRY
ED Entered STN: 01 Jun 2007
CN Benzamide, N-[2,3,4,5-tetrahydro-1-(3-methylbutyl)-1H-1-benzazepin-5-yl]-
(CA INDEX NAME)
MF C22 H28 N2 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,649

L5 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 936333-25-4 REGISTRY
ED Entered STN: 01 Jun 2007
CN Benzamide, N-[2,3,4,5-tetrahydro-1-(2-phenylethyl)-1H-1-benzazepin-5-yl]-
(CA INDEX NAME)
MF C25 H26 N2 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT